Medexus Pharmaceuticals (TSE:MDP) Trading Up 6.5%

Medexus Pharmaceuticals Inc. (TSE:MDP)’s share price shot up 6.5% during mid-day trading on Friday . The stock traded as high as C$1.70 and last traded at C$1.65. 74,660 shares were traded during trading, an increase of 36% from the average session volume of 55,010 shares. The stock had previously closed at C$1.55.

Medexus Pharmaceuticals Trading Up 6.5 %

The firm has a market cap of C$40.36 million, a PE ratio of 4.13 and a beta of 1.85. The business’s 50-day simple moving average is C$1.65 and its 200 day simple moving average is C$2.01.

Medexus Pharmaceuticals (TSE:MDP) last released its quarterly earnings data on Wednesday, February 7th. The company reported C($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.10 by C($0.13). The business had revenue of C$34.33 million for the quarter, compared to the consensus estimate of C$42.33 million. Medexus Pharmaceuticals had a net margin of 5.08% and a return on equity of 26.14%. Analysts expect that Medexus Pharmaceuticals Inc. will post 0.1087405 earnings per share for the current year.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.